Windtree Therapeutics INC /DE/ Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 2.55% Passive Stake in Windtree Therapeutics
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 2.55% in Windtree Therapeutics, Inc. as of December 31, 2024.